

International Conference on the Management of Liver Diseases

Organised by
Pr Patrick Marcellin

Association for the Promotion
of Hepatologic Care (APHC)

PROGRAM

Scientific Committee:

Marc BOURLIERE, President, *France*
Massimo COLOMBO, *Italy*
Rafael ESTEBAN, *Spain*
Graham FOSTER, *UK*
Michael FRIED, *USA*
Michael MANNS, *Germany*
Didier SAMUEL, *France*
Lawrence SERFATY, *France*

Organising Committee:

Aouatef Coudert
Ashiq Mohamed
Françoise Perrot

Hôpital Beaujon,
APHP - INSERM CRI - Université de Paris

13:00 - 13:05 INTRODUCTION

Patrick MARCELLIN (France)

13:05 - 14:00 LESSONS FROM COVID-19

Chairs: Antonio CRAXI (Italy) and Marc BOURLIERE (France)

The COVID-19, NASH and other liver diseases: lessons learned Thomas BERG (Germany)

The impact of COVID-19 on the HCV elimination program Antonio CRAXI (Italy)

Making a sustainable impact on Covid-19 Raymond SCHINAZI (USA)

DISCUSSION

14:00 - 15:00 HEPATITIS B

Chairs: Rafael ESTEBAN (Spain) and Seng Gee LIM (Singapore)

Is elimination of HBV realistic ? Seng Gee LIM (Singapore)

NUC therapy: the role of TAF Maria BUTI (Spain)

New drugs for HBV cure Fabien ZOULIM (France)

DISCUSSION

15:00 - 15:10 BREAK & VISIT OF THE BOOTHS

15:10 - 15:50 AWARD PHC 2021

Chair: Patrick MARCELLIN (France)

HBV cure: How and when? Geoffrey DUSHEIKO (UK)

15:50 - 17:00 HEPATITIS DELTA

Chairs: Mario RIZZETTO (Italy) and Tarik ASSELAH (France)

The emerging issue of Hepatitis Delta in Asia Tawesak TANWANDEE (Thailand)

Is Hepatitis Delta underestimated? Georgios PAPATHEODORIDIS (Greece)

New drugs for HDV Tarik ASSELAH (France)

How do I treat my patients ? Heiner WEDEMEYER (Germany)

DISCUSSION

17:00 - 17:15 TAKE HOME MESSAGES

Graham FOSTER (UK)

17:15 - 17:25 BREAK & VISIT OF THE BOOTHS

17:25 - 18:25 MEETING WITH THE 2020 NOBEL PRICE LAUREATES:

Chairs: Thomas BERG (Germany) and Patrick MARCELLIN (France)

Harvey ALTER (USA) Michael HOUGHTON (Canada) Charles RICE (USA)

18:25 - 18:30 CONCLUSION

Patrick MARCELLIN (France)

18:30 - 19:30 ABBVIE SYMPOSIUM

LA MATINÉE FRANCO-AFRICAINE DU PHC 2021

EN COLLABORATION AVEC LA SAHGE ET L'AFEF

08:30 - 08:40 INTRODUCTION

Rhimou ALAOUI (SAHGE), Marc BOURLIÈRE (AFEF) et Patrick MARCELLIN (APHC)

08:40 - 08:50 INVITE D'HONNEUR:

Christian TREPO (France)

Défis et perspectives dans l'hépatite B

08:50 - 09:50 AVANCEES DANS LE DIAGNOSTIC ET LE PRONOSTIC

Modérateurs: Nabil DEBZI (Algérie) et Marc BOURLIÈRE (France)

Hépatite B et D: Applications des nouveaux marqueurs Françoise LUNEL FABIANI (France)

NASH: Marqueurs non invasifs

Vincent LEROY (France)

CHC: Progrès de l'imagerie

Valérie VILGRAIN (France)

DISCUSSION

09:50 - 10:05 CONFERENCE

Moderateurs: Pape Saliou MBAYE (Sénégal) et Laurent CASTERA (France)

La NASH: Etat des lieux en Afrique

Mohamed TAHIRI (Maroc)

10:05 - 10:10 PAUSE & VISITE DES STANDS

10:10 - 11:10 AVANCEES DANS LE TRAITEMENT

Modérateurs: Nathalie GANNE-CARRIÉ (France) et Jalil BOUBAKER (Tunisie)

Hépatite B: Objectif éradication virologique

Massimo LEVRERO (France)

NASH: Traitement actuel

Jerôme BOURSIER (France)

CHC: Traitement personnalisé

Pierre NAHON (France)

DISCUSSION

11:10 - 11:40 ELIMINATION DES HEPATITES ET ACCES AUX ANTIVIRAUX EN AFRIQUE

Modérateurs: Marie-Jeanne LOHOUES KOUACOU (Côte d'Ivoire) et Jean-Pierre ZARSKI (France)

Hépatite C:

Mustapha BENAZZOUZ (Maroc)

Hépatite B:

Roger SOMBIE (Burkina Faso)

11:40 - 11:50 LES PRINCIPAUX MESSAGES

Victor DE LEDINGHEN (France)

11:50 - 11:55 CONCLUSION

Rhimou ALAOUI (Maroc), Marc BOURLIÈRE (France) et Patrick MARCELLIN (France)

11:55 - 12:00 PAUSE & VISITE DES STANDS

12:00 - 13:00 MYR PHARMACEUTICALS SYMPOSIUM

13:00 - 13:05 INTRODUCTION Patrick MARCELLIN (France)

13:05 - 14:30 IS ELIMINATION OF HCV BY 2030 REALISTIC ?
Chairs: Marc BOURLIERE (France) and Graham FOSTER (UK)

Europe

France Stanislas POL (France)
Western Europe Stefan ZEUZEM (Germany)
Central Europe Robert FLISIAK (Poland)
Eastern Europe Vasily ISAKOV (Russia)

DISCUSSION

Chairs: Robert GISH (USA) and Masao OMATA (Japan)

Other Continents

USA Michael FRIED (USA)
Latin America Raymundo PARANA (Brazil)
Asia Jidong JIA (China)
Egypt Ahmed EL RAY (Egypt)

DISCUSSION

14:30 - 14:50 STATE OF THE ART
Current management of Hepatitis E Jean-Marie PERON (France)

14:50 - 15:00 BREAK & VISIT OF THE BOOTHS

15:00 - 16:00 HCC: ADVANCES IN DIAGNOSIS AND PROGNOSIS
Chairs: Massimo COLOMBO (Italy) and Valérie VILGRAIN (France)
Clinical applications of genetics in HCC Jessica ZUCMAN-ROSSI (France)
The new pathology approach Valérie PARADIS (France)
The digital and imaging Valérie VILGRAIN (France)
DISCUSSION

16:00 - 16:20 STATE OF THE ART LECTURE
Real world evidence in HCC Michael FRIED (USA)

16:20 - 17:55 HCC: EVOLVING CONCEPTS IN THERAPY
Chairs: Didier SAMUEL (France) and Raymond CHUNG (USA)
The role of DAAs George LAU (Hong Kong)
Trans-Arterial Radioembolisation (TARE) Vincenzo MAZZAFERRO (Italy)
Changing indications for liver transplantation Didier SAMUEL (France)
New algorithm for systemic therapy Peter GALLE (Germany)
Immunotherapy today Sandrine FAIVRE (France)
DISCUSSION

17:55 - 18:05 BREAK & VISIT OF THE BOOTHS

18:05 - 18:25 TAKE HOME MESSAGES Marc BOURLIERE (France)

18:25 - 18:30 CONCLUSION Patrick MARCELLIN (France)

18:30 - 19:30 GILEAD SYMPOSIUM

19:30 - 20:00 ROCHE SYMPOSIUM

12:30 - 13:00 EIGER BIOPHARMACEUTICALS SYMPOSIUM

13:00 - 13:05 INTRODUCTION

Patrick MARCELLIN (France)

13:05 - 14:10 NAFLD/NASH: PHYSIOPATHOLOGY, DIAGNOSIS AND OUTCOME

Chairs: Michael MANNIS (Germany) and Massimo PINZANI (UK)

Physiopathology of NAFLD and NASH

Massimo PINZANI (UK)

Natural history of NASH and HCC

Elisabetta BUGIANESI (Italy)

Non-invasive markers in NAFLD

Laurent CASTERA (France)

How to make NAFLD a global public health priority ?

Jeffrey LAZARUS (Spain)

DISCUSSION

14:10 - 14:30 STATE OF THE ART LECTURE

Pathology of NAFLD/NASH revisited

Valérie PARADIS (France)

14:30 - 14:40 BREAK & VISIT OF THE BOOTHS

14:40 - 15:50 NAFLD/NASH: MULTIDISCIPLINARY MANAGEMENT OF A SYSTEMIC DISEASE

Chairs: Francesco NEGRO (Switzerland) and Lawrence SERFATY (France)

The hepatologists

Ana Carolina CARDOSO (Brazil)

Manuel ROMERO GOMEZ (Spain)

The diabetologist

Michael RODEN (Germany)

The surgeon

François PATTOU (France)

DISCUSSION

15:50 - 16:10 STATE OF THE ART LECTURE

New drugs for NASH

Arun SANYAL (USA)

16:10 - 16:20 BREAK & VISIT OF THE BOOTHS

16:20 - 17:20 END STAGE LIVER DISEASE

Chairs: Shiv SARIN (India) and Richard MOREAU (France)

Management of hepatorenal syndrome

Adrian GADANO (Argentina)

Is encephalopathy under-estimated ?

Dominique THABUT (France)

Acute-on-chronic liver failure

François DURAND (France)

DISCUSSION

17:20 - 17:40 STATE OF THE ART LECTURE

Optimal management of cholangiocarcinoma

Ulrich BEUERS (Netherlands)

17:40 - 17:50 BREAK & VISIT OF THE BOOTHS

17:50 - 19:20 R&D : THE DRUGS PIPELINE PRESENTED BY COMPANIES

Chairs: Arun SANYAL (USA) and Raymond SCHINAZI (USA)

Gilead's Commitment to Liver Disease

Tram TRAN, VP Medical Affairs

Madrigal: Advancing Resmetirom in Phase 3 Trials for Non-cirrhotic NASH with Liver Fibrosis

Rebecca TAUB, President of Research & Development

Pfizer interest in NASH

Dominique MENUET, Sr Medical Manager CVMet Early Pipeline

Fady NTANIOS, Sr Director CVMet Early Pipeline

Assembly Biosciences: Developing Innovative Therapeutics Targeting Chronic HBV Infection

Luisa STAMM, Chief Medical Officer

Eiger BioPharmaceuticals: Developing Two Foundational Treatments for HDV

Pr. Jeffery S. GLENN, Stanford University

Janssen TBD

19:20 - 19:30 THE BEST POSTER PRICE

Patrick MARCELLIN (France)

19:30 - 19:50 TAKE HOME MESSAGES

Michael FRIED (USA)

19:50 - 20:00 CONCLUSION

Patrick MARCELLIN (France)

SYMPOSIA

Monday March 8th 2021

18:30 - 19:30 **ABBVIE SYMPOSIUM**

Live



Driving change in the 'new normal' - the importance of simplified and decentralized HCV care

Welcome and Introduction
The lasting impact of COVID-19 on HCV care and elimination efforts
Simplified, decentralized care - how do DAAs make this feasible ?
Evolving your role as an HCV specialist: from concept to practice
Audience Q&A

Marc BOURLIERE (chair, France)
Robert FLISIAK (Poland)
Marc BOURLIERE (France)
Joaquin CABEZAS (Spain)
All speakers/ Marc BOURLIERE (France)

Tuesday March 9th 2021

12:00 - 13:00 **MYR Pharmaceuticals SYMPOSIUM**



The management of the delta viral hepatitis

Introduction
International review of the delta through a clinical case
Sharing of experience with 2 clinical cases
Audience Q&A

Nathalie GANNE-CARRIE (France)
Fabien ZOULIM (France)
Isabelle ROSA (France) & Marie-Noelle HILLERET (France)

18:30 - 19:30 **GILEAD SYMPOSIUM**

Live



New advances in liver disease care

Chairs: Tarik ASSELAH (France) & Maria BUTI (Spain)

On the road to Hepatitis C elimination : what challenges for psychiatric patients ?
New insights into NASH management
Current PSC management challenges
Audience Q&A

Stanislas POL (France)
Helena CORTEZ-PINTO (Portugal)
Vincent LEROY (France)

19:30 - 20:00 **ROCHE SYMPOSIUM**



Immunotherapy combination: the revolution in unresectable HCC

Marc BOURLIERE (France) & Julien EDELINE (France)
Systemic therapy for patients with unresectable HCC
What are changes in the daily practices ? Cross view from hepatologist and oncologist. Discussion around case studies
Audience Q&A

Wednesday March 10th 2021

12:30 - 13:00 **EIGER BioPharmaceuticals SYMPOSIUM**

Live



Hepatitis Delta: What the future holds ?

Chairs: Tarik ASSELAH (France) & Pietro LAMPERTICO (Italy)

The present state of hepatitis Delta: epidemiology, diagnosis, and current treatments
Can current research change the face of hepatitis Delta ?
D-LIVR patient characteristics
Audience Q&A

Tarik ASSELAH (France)
Ohad ETZION (Israel)
Pietro LAMPERTICO (Italy)

CONGRESS ACCREDITATION



The PARIS HEPATOLOGY CONFERENCE, PARIS, France, 08/03/2021-10/03/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 11 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.”

“Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities. Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

This 14th PHC is supported by unrestricted grants from :

